L&C BIO said on the 5th that it joined the business delegation visiting China. L&C BIO has a subsidiary and a production base in China. It holds human tissue medical devices approved by the National Medical Products Administration (NMPA) of China.
China's aging population is increasing medical demand. The company discussed cooperation plans with local hospitals, distributors, and medical groups. It plans to expand its portfolio of regenerative medicine and treatments based on human tissue in China.
A company official said, "We plan to expand our business in China with a localization strategy."
※ This article has been translated by AI. Share your feedback here.